NCT01907087
CLN2, Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2, Jansky-Bielschowsky Disease, Batten Disease, CLN2 Disease
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
The purpose of this study is to determine whether BMN 190 is safe and effective in the treatment of patients with Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) disease.
All
3 Years to 15 Years
No
BMN 190
Phase 1/Phase 2
Interventional
24
2013-09
2019-03-08
Columbus, Ohio, United States
Hamburg, , Germany
Rome, , Italy
London, , United Kingdom
London, , United Kingdom
By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.
*required fields
"*" indicates required fields